Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01118338 · ClinicalTrials.gov registry record · NA

Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses

A NA study, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
376
Enrollment target

NCT01118338: Completed NA study, sponsored by Bausch & Lomb Incorporated.

NCT01118338 is a NA study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 376 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01118338, a NA study, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
376 participants
Enrollment target

Study Summary

The objective of this one month study is to evaluate the product performance of a redesigned PureVision Contact Lens compared to the PureVision Contact Lens when worn on a daily wear basis by wearers of contact lenses.

Primary Outcome

Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints and 100 denoting the most favorable rating. The generic scale was comprised of 14 separate questions, where each assessed the denoted symptom/complaint with a score between 0 and 100. The total score was not calculated.

Interventions

  • DEVICE Redesigned Purevision Contact Lens
  • DEVICE PureVision Contact Lens

Trial Details

FieldValue
Enrollment Target 376 participants
Start Date 2010-05
Est. Completion 2010-07
Phase NA
Bausch & Lomb Incorporated

174 total trials

What the finished NCT01118338 record still lists

NCT01118338 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 2 interventions - of which Redesigned Purevision Contact Lens is the first listed.

NCT01118338 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01118338 about?

NCT01118338 is a clinical study titled "Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses". The objective of this one month study is to evaluate the product performance of a redesigned PureVision Contact Lens compared to the PureVision Contact Lens when worn on a daily wear basis by wearers of contact lenses.

What is the current status of trial NCT01118338?

This trial is currently completed. It is a NA study. The enrollment target is 376 participants. The study started on 2010-05. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01118338?

The interventions under investigation include: Redesigned Purevision Contact Lens (DEVICE), PureVision Contact Lens (DEVICE).

Who is sponsoring clinical trial NCT01118338?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01118338's enrollment target sits among peer trials

376 274th of 2000 higher than 1,725 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03102125 · 376 participants · Phase 4

    Allograft Dysfunction in Heart Transplant

  • NCT05055297 · 376 participants · NA

    SELUTION4BTK Trial

  • NCT05912647 · 376 participants · NA

    Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes

  • NCT05963971 · 376 participants · NA

    A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01118338, the US trial registry maintained by the National Library of Medicine. NCT01118338 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.